Notice of Allowability	Application No.	Applicant(s)	Applicant(s)	
	09/684,599	PASTAN ET AL.	PASTAN ET AL.	
	Examiner	Art Unit		
	Susan Ungar	1642		
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate comming IGHTS. This application is s	n this application. If not included unication will be mailed in due co	ourse. THIS	
1. This communication is responsive to <u>Amendment filed Apr</u>	il 11, 2007.			
2. The allowed claim(s) is/are 47-50, now 1-4, respectively.				
<ul> <li>3.  Acknowledgment is made of a claim for foreign priority ur</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> <li>2.  Certified copies of the priority documents have</li> <li>3.  Copies of the certified copies of the priority documents have</li> <li>International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>	been received. been received in Application	on No. <u>08/766,271</u> .	on from the	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file IENT of this application.	a reply complying with the requ	irements	
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXA es reason(s) why the oath o	AMINER'S AMENDMENT or NO reclaration is deficient.	TICE OF	
<ul> <li>5. CORRECTED DRAWINGS ( as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in the deposit of the deposit o</li></ul>	con's Patent Drawing Review s Amendment / Comment or 84(c)) should be written on the header according to 37 CF sit of BIOLOGICAL MATE	in the Office action of the drawings in the front (not the book 1.121(d).  ERIAL must be submitted. No	·	
Attack word (a)				
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of In	formal Patent Application		
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. 🔲 Interview Si	view Summary (PTO-413),		
3. Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Date 7. ⊠ Examiner's Amendment/Comment			
Paper No./Mail Date  4.  Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's 9. □ Other	Statement of Reasons for Allows  SUSAN UNGAR, PH.D	ance	
		THIM SHALL HAVING HE	•	

Application/Control Number: 09/684,599

Art Unit: 1642

2. The Amendment filed April 11, 2007 in response to the Office Action of May 10, 2006 is acknowledged and has been entered. Previously pending claims 1-46 were canceled and claims 47-50 were added. Claims 47-50 are currently under prosecution.

3. The oath or declaration is defective. A new oath or declaration in compliance with 37 C.F.R. → 1.67(a) identifying this application by its Serial Number and filing date is required. See M.P.E.P. → 602.01 and 602.02.

The oath or declaration is defective because:

Non-initialed and/or non-dated alterations have been made to the oath or declaration. See 37 CFR 1.52(c).

This application will not be passed to issue until a new declaration is submitted.

4. The following is an Examiner's Statement of Reasons for Allowance:

Cancellation of the previously pending claims overcomes the rejection of those claims under 35 USC 112, first paragraph as well as under 35 USC 102(b). Further, a review of Chang et al, PNAS, 1996, 93:136-140, of record clearly reveals the instantly claimed sequence of SEQ ID NO:2, see Figure 2, p. 138 and demonstrates that the polypeptide is a 69kD polypeptide (see Figure 2, p. 138), overcoming the rejection of the claims under 102(b) given that Chang et al, Cancer

Art Unit: 1642

Research, 1992 discloses only a 40 kD polypeptide which clearly cannot be the full length polypeptide currently claimed.

5. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (703) 305-2181. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (571) 272-0837. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley, can be reached at 571-272-0878. The fax phone number for this Art Unit is (571) 273-8300.

Effective, February 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this

Application/Control Number: 09/684,599

Art Unit: 1642

application, all further correspondence regarding this application should be

Page 4

directed to Group Art Unit 1642.

Susan Ungar

Primary Patent Examiner

July 17, 2007